Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Arsenic Polyoxotungstate-Zeolitic Imidazolate Framework-8 As a Potential Selective Anti-Cancer Nano Platform Publisher



Moazeni Bistgani Z1 ; Shafiee F2 ; Varshosaz J3 ; Kazemian H4, 5 ; Tangestaninejad S6 ; Rostami M7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  2. 2. Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  3. 3. Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  4. 4. Northern Analytical Lab Services (Northern BC’ Environmental & Climate Solutions Innovation Hub), University of Northern British Columbia, Prince George, BC, Canada
  5. 5. Chemistry Department, Faculty of Science and Engineering, University of Northern British Columbia, Prince George, BC, Canada
  6. 6. Department of Chemistry, Catalysis Division, University of Isfahan, Isfahan, 81746-73441, Iran
  7. 7. Novel Drug Delivery Systems Research Centre and Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Inorganic and Organometallic Polymers and Materials Published:2023


Abstract

A pH-sensitive nanoplatform of Pegylated Zeolitic Imidazolate Framework-8 (ZIF-8/PEG) was selected to modulate the cytotoxicity profile of arsenic polyoxotungstate (K6As2W18O62, KAW). The final nanoplatforms (NPs) showed a high loading content (31%) and a pH-responsive release of KAW. The in vitro cytotoxicity experiments showed that the IC50 decreased to about half in designed NPs on MDA-MB-231 cancer cells with a better level of cellular uptake (92%) than in control KAW (62%). Also, the final pegylated NPs were safer than free KAW on normal cells (85 mg/mL versus 45 mg/mL). The in vitro study confirmed the higher potency of the designed NPs against breast cancer cells with lower side effects than free KAW. Graphical Abstract: [Figure not available: see fulltext.] © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Experts (# of related papers)
Other Related Docs
10. Novel Tocopherol Succinate-Polyoxomolybdate Bioconjugate As Potential Anti-Cancer Agent, Journal of Inorganic and Organometallic Polymers and Materials (2021)
26. Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review, Iranian Journal of Public Health (2022)